In summary, these results suggest that the SLC7A11 inhibitor sulfasalazine effectively suppressed the growth of osteosarcoma in vitro and in vivo, indicating the potential for clinical translation of sulfasalazine into osteosarcoma treatment. This evidence concerns the gene SLC7A11 and osteosarcoma.